Skip to main content
A phase i dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma
Published Web Location
http://europepmc.org/articles/PMC4832308?pdf=renderNo data is associated with this publication.
Abstract
© 2015 American Cancer Society.BACKGROUND The mammalian target of rapamycin (mTOR) pathway is essential for tumor development, yet mTOR inhibitors have yielded modest results. This phase 1 study investigated the mTORC1/mTORC2 inhibitor CC-223 in patients w
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.